All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Andrew M. Brunner, Massachusetts General Hospital, Boston, US. We asked, Why is TIM-3 a good target for treating patients with high-risk MDS?
Why is TIM3 a good target for treating patients with high-risk MDS?
Current treatments available for patients with high-risk MDS achieve low overall response rates. In this video, Brunner explains the rationale for targeting TIM-3 in acute myeloid leukemia/MDS.
Targeted therapeutics in MDS – what’s the current state of play?
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub podcast channel spoke to Dr David Sallman, Moffitt Cancer Center, Tampa, US, and Professor Amer...
What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?
During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Amer Zeidan, Yale School of Medicine, New Haven, US. We asked: What does...
Subscribe to get the best content related to MDS delivered to your inbox